

13th September, 2021

To whom it may concern,

Re: "Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn's Disease"

This letter is to confirm that according to the Ethics Board Approval for this retrospective cross-sectional study, individual patient consent was not required to be obtained.

Yours sincerely,



Dr Bonita Gu

On behalf of **A/Professor Susan Connor**

Conjoint A/Professor UNSW/ Senior Staff Specialist

Department of Gastroenterology & Hepatology

Clinic 123 Level 1 Liverpool Hospital Liverpool NSW 2170

Locked Bag 7103. Liverpool BC NSW 1871

Tel +61-2- 8738 4085 | Fax +61-2- 8738 3094 |

Working together to provide expert individualised care for Crohn's and Colitis

www.health.nsw.gov.au

A/Prof Susan Connor
Senior Staff Specialist
MBBS (Hons1 UNSW)
BMed Sci (UNSW)
FRACP
PhD (UNSW)
Provider No 2019835Y

Dr Watson Ng
Staff Specialist
MBBS (Hons USYD)
FRACP
PhD (UNSW)
Provider No 2170784T

Dr Astrid-Jane Williams
Staff Specialist
BSc (UQ)
MBBS (UQ)
FRACP
MHSc (UBC)
Provider No 4117236F

Alexandra Sechi
IBD Clinical Nurse Consultant
B Nursing (UOW), Grad Dip Nursing
(Gastroenterology) (UQ)

Gordana Kuzet
IBD Clinical Nurse Specialist
B Nursing (WSU)

Aura Cabaero
IBD Registered Nurse
B Nursing (USyd)